MASI
NASDAQMasimo Corporation
Price$178.82+3.44 (+1.96%)
2026-03-042026-06-05
News · 26 weeks46-92%
2025-12-142026-06-07
Mix2890d
- Insider14(50%)
- Other7(25%)
- SEC Filings6(21%)
- Analyst1(4%)
Latest news
25 items- SECSEC Form SD filed by Masimo CorporationSD - MASIMO CORP (0000937556) (Filer)
- SECSEC Form SCHEDULE 13G filed by Masimo CorporationSCHEDULE 13G - MASIMO CORP (0000937556) (Subject)
- SECSEC Form 10-Q filed by Masimo Corporation10-Q - MASIMO CORP (0000937556) (Filer)
- INSIDERDirector Scannell Timothy J converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERDirector Lane Wendy E converted options into 1,225 shares, increasing direct ownership by 89% to 2,608 units (SEC Form 4)4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERChairman of the Board Brennan Michelle converted options into 1,225 shares, increasing direct ownership by 17% to 8,543 units (SEC Form 4)4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERChief Human Resources Officer Hellmann Elisabeth A converted options into 335 shares and covered exercise/tax liability with 121 shares (SEC Form 4) to satisfy tax liability4 - MASIMO CORP (0000937556) (Issuer)
- SECMasimo Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - MASIMO CORP (0000937556) (Filer)
- PRMasimo Shareholders Approve Acquisition by DanaherMasimo Corporation (NASDAQ:MASI) ("Masimo"), a leading global innovator in patient monitoring, today announced that its stockholders voted in favor of the proposal to adopt the previously announced Agreement and Plan of Merger, dated February 16, 2026 (the "Merger Agreement"), by and among Masimo, Danaher Corporation ("Danaher") (NYSE:DHR) and Mobius Merger Sub, Inc. (the "Merger Sub") at Masimo's special meeting of stockholders held virtually on May 1, 2026 (the "Special Meeting"). Katie Szyman, Chief Executive Officer of Masimo, stated: "We thank our shareholders for their strong support of this important milestone for Masimo. The Merger delivers compelling value and positions Masimo fo
- SECAmendment: SEC Form 10-K/A filed by Masimo Corporation10-K/A - MASIMO CORP (0000937556) (Filer)
- PRMasimo SET® Pulse Oximetry Performed Accurately on Hospitalized Newborns of All Skin Tones in Largest-Ever Prospective Real-World StudyNICU Study Adds to the Evidence Demonstrating SET®'s Accuracy in Challenging Real-World Settings, With No Clinically Significant Differences in Performance Across Skin Pigmentation Categories or Race and Zero Occult Hypoxemia in Black or Hispanic Newborns Masimo (NASDAQ:MASI) today announced the findings of a study evaluating the accuracy of Masimo SET® pulse oximetry among critically ill neonates and demonstrating less than 1% overall statistical bias. Importantly, there were no clinically meaningful skin pigmentation-related discrepancies and no occult hypoxemic events among Black or Hispanic patients, and in only one Caucasian patient overall. The Neonatal Pulse Oximetry Accuracy and D
- SECSEC Form DEFA14A filed by Masimo CorporationDEFA14A - MASIMO CORP (0000937556) (Filer)
- SECMasimo Corporation filed SEC Form 8-K: Other Events8-K - MASIMO CORP (0000937556) (Filer)
- PRTelix Strengthens Board with Additional Director AppointmentsMELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning: Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years' experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ:COO), a medical technology company, and also served as an independent director for Medidata
- SECSEC Form DEFM14A filed by Masimo CorporationDEFM14A - MASIMO CORP (0000937556) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Masimo CorporationSCHEDULE 13G/A - MASIMO CORP (0000937556) (Subject)
- ANALYSTMasimo downgraded by Raymond JamesRaymond James downgraded Masimo from Outperform to Mkt Perform
- SECSEC Form PREM14A filed by Masimo CorporationPREM14A - MASIMO CORP (0000937556) (Filer)
- INSIDERCEO Szyman Catherine M. covered exercise/tax liability with 1,069 shares and converted options into 2,101 shares, increasing direct ownership by 16% to 7,605 units (SEC Form 4)4 - MASIMO CORP (0000937556) (Issuer)
- INSIDEREVP & Chief Financial Officer Young Micah W converted options into 873 shares and covered exercise/tax liability with 471 shares, increasing direct ownership by 2% to 25,656 units (SEC Form 4)4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERSEC Form 4 filed by Director by deputization Politan Capital Management Lp4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commerical Officer Meehan Greg Allen4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERSEC Form 4 filed by Chief Marketing Officer Benner Tim4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERSEC Form 4 filed by Chief Human Resources Officer Hellmann Elisabeth A4 - MASIMO CORP (0000937556) (Issuer)
- INSIDERSEC Form 4 filed by EVP, Operations Sampath Anand4 - MASIMO CORP (0000937556) (Issuer)
MASI FAQ
7 questionsWhat does Masimo Corporation do?
Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate...Where does MASI stock trade?
Masimo Corporation (MASI) is listed on NASDAQ.What sector and industry is MASI in?
Masimo Corporation operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Masimo Corporation go public?
Masimo Corporation (MASI) completed its IPO in 2007.What are analysts saying about MASI?
Masimo Corporation has had 8 recent analyst actions on file. The most recent action was from Raymond James: Mkt Perform on 2026-03-27.What companies are similar to MASI?
Notable peers in the same industry include MDT (Medtronic plc.), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation), SLNO (Soleno Therapeutics Inc.). Compare MASI side-by-side with any of them on Quantisnow.How can I track MASI on Quantisnow?
Quantisnow aggregates Masimo Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MASI to receive live email and push alerts on every new disclosure.